Discover
CBIO
Crescent Biopharma, Inc.
17.08
2 x 13.14
2 x 21.79
bid
ask
-
0.92
5.11%
2 @ 04:00 PM
16.95 -0.13 (0.76%)
| Ytd | 44.01% | |
| 1y | 5.76% |
16.97
day range
18.52
8.72
52 week range
27.41
| Open | 18.00 | Prev Close | 18.00 | Low | 16.97 | High | 18.52 | Mkt Cap | 470.98M |
| Vol | 179.07K | Avg Vol | 315.55K | EPS | -5.88 | P/E | N/A | Forward P/E | -17.04 |
| Beta | 1.29 | Short Ratio | 0.19 | Inst. Own | 8.75% | Dividend | 15.94 | Div Yield | 792.92 |
| Ex Div Date | 01-13 | Earning | N/A | 50-d Avg | 19.49 | 200-d Avg | 14.47 | 1yr Est | 0.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2023-10-26 | 2023-09 | -0.05 | N/A | N/A | N/A |
| 2023-08-14 | 2023-06 | -0.07 | N/A | N/A | N/A |
| 2023-05-15 | 2023-03 | 0 | N/A | N/A | N/A |
| 2023-03-30 | 2022-12 | 0 | N/A | N/A | N/A |
| 2022-11-14 | 2022-09 | 0 | N/A | N/A | N/A |
| 2022-08-15 | 2022-06 | -0.22 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2021-11-14 | Raymond James | Downgrade | Outperform | Market Perform |
| 2021-08-05 | Raymond James | Upgrade | Outperform | |
| 2021-04-28 | Raymond James | Upgrade | Outperform | |
| 2021-02-09 | Piper Sandler | Upgrade | Overweight | |
| 2021-02-03 | Raymond James | Upgrade | Outperform | |
| 2019-01-03 | Oppenheimer | Upgrade | Outperform |
Profile
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-01-06 | HUNT ANDREA | Director | 28.23K | Stock Award(Grant) |
| 2022-01-06 | LING GEOFFREY M. D. | Director | 31.79K | Stock Award(Grant) |
| 2022-01-06 | WILLIAMS EDDIE | Director | 34.80K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2023-06-29 | Renaissance Technologies, LLC | 774.39K | 272.27K | 2.04% |
| 2023-06-29 | Geode Capital Management, LLC | 270.03K | 94.94K | 0.71% |
| 2023-06-29 | Blackrock Inc. | 153.66K | 54.03K | 0.40% |
| 2023-06-29 | Acadian Asset Management. LLC | 144.03K | 50.64K | 0.38% |
| 2023-06-29 | Kynam Capital Management, LP | 89.89K | 31.60K | 0.24% |
| 2023-06-29 | Northern Trust Corporation | 86.41K | 30.38K | 0.23% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2023-05-30 | Fidelity Extended Market Index Fund | 160.40K | 35.29K | 0.42% |
| 2023-05-30 | Fidelity Series Total Market Index Fund | 34.51K | 7.59K | 0.09% |
| 2023-05-30 | Fidelity Total Market Index Fund | 35.67K | 7.85K | 0.09% |
| 2023-05-30 | Fidelity NASDAQ Composite Index Fund | 25.12K | 5.53K | 0.07% |
| 2023-08-30 | iShares Core S&P Total U.S. Stock Market ETF | 7.75K | 4.34K | 0.02% |
Dividend
| Dividend | Date |
|---|---|
| 0.0002 | 2023-01-13 |
| 1.43 | 2022-09-22 |
| 0.001 | 2022-09-21 |
| 1.43 | 2022-09-02 |
| 1.6492 | 2015-08-20 |
Split
| Split | Date |
|---|---|
| 1 : 100 | 2025-06-16 |
| 3803 : 1000 | 2022-09-21 |
| 1 : 15 | 2017-02-13 |
| 1 : 7 | 2015-08-21 |